Sodium Oxybate

證據等級: L5

預測適應症: 6 個

Sodium Oxybate: From Narcolepsy with Cataplexy to Insomnia

One-Sentence Summary

Sodium oxybate (marketed as Xyrem/Xywav) is a GABA‑B/GHB receptor agonist currently used to treat narcolepsy with cataplexy and excessive daytime sleepiness, per trial descriptions found in the evidence pack. The TxGNN model predicts it may also be effective for Insomnia, with 13 clinical trials and 13 publications currently associated with this indication — though only one trial (a completed, head‑to‑head Phase 2 RCT vs. zolpidem) is graded as directly and strongly relevant.

Quick Overview

Item	Content
Original Indication	Narcolepsy with cataplexy (per clinical trial descriptions in the evidence pack; not confirmed in local regulatory licensing data — data gap)
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.99% (model rank 201)
Evidence Level	L2
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed DrugBank mechanism-of-action data is currently a data gap for this candidate. Based on information available within the evidence pack itself, sodium oxybate is a GABA‑B and GHB (gamma‑hydroxybutyrate) receptor agonist that is well documented to significantly increase slow‑wave sleep (SWS) and consolidate sleep architecture — this is the same pharmacological property underlying its approved use in narcolepsy (reducing nocturnal sleep fragmentation and daytime sleepiness).

This SWS‑enhancing, sleep‑consolidating mechanism is biologically plausible for insomnia, particularly sleep‑maintenance insomnia, since deepening and stabilizing nighttime sleep addresses the core pathophysiology of the condition. This is directly supported by a completed Phase 2 RCT (NCT00383643) that compared sodium oxybate head‑to‑head with zolpidem (Ambien) in chronic insomnia patients. However, sodium oxybate is a Schedule‑controlled CNS depressant with known risks of respiratory depression, dependence, and nocturnal arousal/parasomnia-type events, so any repurposing case must be weighed against these risks relative to established first‑line hypnotics.

It is also worth noting that of the six diseases TxGNN predicted for this drug, four were assessed as low‑value or misleading signals rather than genuine therapeutic hypotheses: “neurogenic bladder” and “cauda equina syndrome” appear to be false positives with no mechanistic or literature support, while “restless legs syndrome” and “Wernicke‑Korsakoff syndrome” are actually documented adverse effects/toxicity signals of sodium oxybate/GHB in the literature, not treatment opportunities. Only the insomnia and (closely overlapping) “sleep disorder, initiating and maintaining sleep” predictions have genuine mechanistic and evidentiary backing.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00383643	Phase 2	Completed	48	Randomized, double-blind, double-dummy, placebo-controlled comparison of sodium oxybate vs. zolpidem for chronic insomnia — the single most directly relevant trial.
NCT00641186	Phase 2	Completed	30	Open-label trial of sodium oxybate for excessive daytime sleepiness and nocturnal sleep disturbance in mild-to-moderate Parkinson’s disease.
NCT00594256	Phase 2	Completed	8	Open-label pilot of adjunctive sodium oxybate for schizophrenia-associated sleep disturbances and persistent symptoms.
NCT02637648	Phase 3	Unknown	60	Randomized, placebo-controlled trial of sodium oxybate for prophylaxis of headache and associated sleep disturbances in chronic/episodic cluster headache.
NCT04508166	N/A	Completed	27	Cross-over study testing whether deepening sleep (via drug interventions) reduces post-traumatic intrusive memories after trauma exposure.
NCT01041495	Phase 4	Terminated	37	Cyclobenzaprine ER augmentation study for fibromyalgia fatigue/pain; sodium oxybate not the primary intervention.
NCT04803786	N/A	Completed	110	Real-world observational study (TENOR) on patients with narcolepsy transitioning from Xyrem to low-sodium oxybate (Xywav).
NCT06421532	Phase 2	Enrolling by Invitation	60	Investigates whether deepening sleep with low-sodium oxybate enhances glymphatic clearance of amyloid-β in cerebral amyloid angiopathy.
NCT00330291	Phase 2	Withdrawn (n=0)	0	Planned trial of Xyrem for treatment-refractory insomnia due to PTSD; withdrawn before enrollment.
NCT01584934	Phase 4	Withdrawn (n=0)	0	Planned double-blind, placebo-controlled crossover trial of sodium oxybate for chronic fatigue syndrome; withdrawn before enrollment.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40120323	2025	Cohort	J Clin Neurosci	Propensity-matched cohort characterizing treatment patterns and comorbidities of narcolepsy patients treated with immediate-release sodium oxybate.
18852348	2008	Cohort	Arch Neurol	Open-label polysomnographic study of sodium oxybate for excessive daytime sleepiness in Parkinson’s disease, showing effects on sleep architecture.
20166851	2010	Review	Expert Opin Emerging Drugs	Reviews emerging pharmacological treatments for narcolepsy and related disorders, including sodium oxybate’s mechanism.
26171909	2015	Review (Cochrane)	Cochrane Database Syst Rev	Systematic review of effects of opioid, hypnotic and sedating medications (including GABA-ergic agents) on sleep-disordered breathing.
11174231	2001	Case Report	Ann Emerg Med	Describes the GHB (sodium oxybate active moiety) withdrawal syndrome — relevant safety signal for dependence risk.
37590830	2023	Review	Continuum (Minneap Minn)	Comprehensive review of pediatric sleep disorders including insomnia, narcolepsy, and treatment approaches.
18805301	2008	Review	Rev Neurol	Review of narcolepsy with cataplexy, including associated sleep-maintenance insomnia and pharmacological management.
31526967	2019	Case Report	Sleep Medicine	Case report of sodium oxybate used to treat severe sleep initiation failure in a child with EBV encephalitis affecting the sleep-wake regulation system.
30214155	2018	Review	Drug Des Devel Ther	Reviews pitolisant’s place in narcolepsy therapy, contextualizing sodium oxybate as an alternative treatment for sleep disturbance.
21815499	2011	Review	Rev Med Suisse	Discusses the bidirectional relationship between chronic pain and sleep disorders, referencing hypnotic treatment strategies.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale:

The only directly relevant evidence is a single completed Phase 2 RCT (n=48, 2006–2009) against zolpidem — supportive but not sufficient on its own (L2), and most other trials in the evidence pack are indirect (Parkinson’s, schizophrenia, fibromyalgia, PTSD) rather than primary-insomnia populations.
A Blocking data gap exists for local regulatory warning/contraindication information (DG001), which prevents completion of even a preliminary safety assessment (S1) — this alone precludes advancing past Hold.
Sodium oxybate is a controlled CNS depressant with documented dependence, respiratory depression, and paradoxical sleep-disturbance risks (e.g., restless legs syndrome as a reported side effect), which must be weighed against existing first-line insomnia therapies before any advancement.

To proceed, the following is needed:

Local drug label / regulatory warning and contraindication data (DG001, blocking)
Confirmed mechanism-of-action documentation from DrugBank (DG002)
A larger, confirmatory, insomnia-specific RCT (the existing trial is small, dated, and single-site in design characteristics)
A formal risk–benefit/safety review addressing abuse potential, dependence, and comparative safety vs. standard hypnotics (e.g., zolpidem, eszopiclone) given the drug’s controlled-substance status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.